

April 18, 2022

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.  
 Corporate Representative Atsushi Udoh, President and Representative Director  
 (Prime Market of Tokyo Stock Exchange Securities Code: 8129)  
 Contact: Makoto Kawamura, Director and General Manager, Corporate Management Division and Corporate Planning and Investor Relations Department  
 (TEL: 81-3-6838-2803)

## Notice Regarding Revision of the Full-year Earnings Forecasts for the Fiscal Year Ended March 2022

TOHO HOLDINGS CO., LTD. is pleased to announce that, in the light of matters such as the recent trends in the Company's performance, it has revised its forecasts of consolidated results for the fiscal year ended March 2022, which were announced on August 6, 2021, as below.

### 1. The Revision of the Full-year Earnings Forecasts for the Fiscal Year Ended March 2022

(From April 1, 2021 to March 31, 2022)

	Net Sales	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Net Income per Share
	Million yen	Million yen	Million yen	Million yen	Yen
Previous forecast (A)	1,192,000	6,400	11,900	7,400	104.92
Revised forecast (B)	1,265,000	12,100	17,700	12,800	181.48
Increase/Decrease (B-A)	73,000	5,700	5,800	5,400	
Change (%)	6.1	89.1	48.7	73.0	
(Reference) Result of FY ended March 2021	1,210,274	4,303	10,289	4,989	70.77

### 2. Reason for the Revision

The consolidated results for the fiscal year ended March 2022 exceeded our expectations due to the following factors, in addition to the recovery trend in the effects of limited clinic visits by patients associated with the spread of COVID-19.

- (1) Full-scale operation of the TBC DynaBASE contributed to the expansion of products handled and the low-cost and efficient distribution systems, including small-group operation, no inspection and direct delivery from the center.
- (2) Steady expansion of the customer support systems contributed significantly to the bottom line of the Group's profits.
- (3) Handling of specialty pharmaceuticals and other products was expanded as a result of the evaluation on the Group's logistics functions and price control system by pharmaceutical manufacturers.
- (4) Sales of therapeutic drugs, reagents, kits, and other products related to COVID-19 grew significantly.
- (5) We promoted the systematic reduction of cross-shareholdings and sold all shares of 14 stocks and part of 1 stock during the fiscal year under review, resulting in a gain on sale of investment securities of approximately 2.7 billion yen.

As a result, net sales, operating profit, ordinary profit, profit attributable to owners of parent and net income per share are estimated to have surpassed previously announced forecasts.

Considering these situations, we have revised the full-year earnings forecasts for the fiscal year ended March 2022, which were announced on August 6, 2021.

(Note) The above earnings forecasts have been prepared based on information available as of the announcement date of this document. Actual performance may differ from the forecasted figures for various reasons.